iBio, Inc. (IBIO) stock

IBIONasdaqPharmaceutical PreparationsFiscal year ends June 30

Financials through Q1 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 9/30

$0.73−0.03 (-4.00%)

Close on Nov 13, 2026Market cap $47.05MP/E –Yield –

iBio EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

iBio has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is IBIO.

Revenue growth115.0% · median -35.6%

Operating margin-3491.0% · median -3982.7%

Net margin-3244.2% · median -1731.7%

Advertisement
300 × 250

See a number that looks wrong?